The American Journal of Medicine
Volume 121, Issue 4 , Pages 265-271 , April 2008

Oral Direct Renin Inhibition: Premise, Promise, and Potential Limitations of a New Antihypertensive Drug

  • Moiz M. Shafiq, MD
    • ,
  • Dileep V. Menon, MD
    • ,
  • Ronald G. Victor, MD

      Affiliations

    • Corresponding Author InformationReprint requests should be addressed to Ronald G. Victor, MD, Internal Medicine, Chief, Hypertension Division, Norman & Audrey Kaplan Chair in Hypertension, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-8586.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funded by the National Institutes of Health training grant in cardiovascular disease, T32-HL07360-29 (Dr Shafiq), American Society of Hypertension Fellowship grant (Dr Menon), and National Institutes of Health RO-1 HL044010 and the Donald W. Reynolds Foundation (Dr Victor). Dr Victor is on the Scientific Advisory Board of Novartis and CVRx, and is the recipient of research grants from Pfizer and Aetna Foundation.

PII: S0002-9343(07)01189-8

doi: 10.1016/j.amjmed.2007.11.016

The American Journal of Medicine
Volume 121, Issue 4 , Pages 265-271 , April 2008

Article Tools

* Image Usage & Resolution